MET and non-small cell lung carcinoma: Generally speaking, in approximately 3%–4% of NSCLC patients, the presence of METex14 skipping mutation is observed, which rarely coexists with other known driver mutations in NSCLC, except for MET amplification (Cancer Genome Atlas Research Network, 2014; Baldacci et al., 2018; Frampton et al., 2015; Tong et al., 2016).